CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0002015: DysphagiaHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1332 Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D003680 Deglutition Disorders NIH 1.00

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Oropharyngeal Dysphagia in Patients Infected by SARS-CoV-2: Prevalence and Needs of Compensatory Treatment of Patients Admitted by COVID-19 in the Consorci Sanitari Del Maresme

Background: Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute hospitals to rehabilitation centers, nursing homes or other facilities. All these situations are common for COVID-19 patients that are currently filling our hospitals due to the pandemic expansion of SARS-CoV-2. OD is associated to prolonged hospitalization, dehydration and severe nutritional and respiratory complications -aspiration pneumonia-, hospital readmissions and mortality. Aim: to assess the prevalence of OD in these patients and to know their needs of compensatory treatment. Methods: observational study in which we will use the volume-viscosity swallowing test (V-VST) to assess the prevalence of OD in admitted patients with confirmed COVID-19 at the Consorci Sanitari del Maresme. We will register also results of the EAT-10, nutritional status (MNA-sf/MUST/NRS), the needs of compensatory treatments of these patients (fluid and nutritional adaptation and use of nutritional supplements) and clinical complications during 6 months follow up.

NCT04346212 Oropharyngeal Dysphagia COVID-19 Sars-CoV2 Nutrition Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)
MeSH:Deglutition Disorders
HPO:Dysphagia Oral-pharyngeal dysphagia

Primary Outcomes

Description: Prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).

Measure: Prevalence of oropharyngeal dysphagia

Time: From April to July 2020.

Secondary Outcomes

Description: Eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points

Measure: Swallowing screening

Time: From April to July 2020.

Description: Percentage of patients with impairements in efficacy and/or safety of swallow.

Measure: Swallowing status.

Time: From April to July 2020.

Description: Nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).

Measure: Nutritonal status of study patient's.

Time: From April to July 2020.

Description: Fluid (volume and viscosity) requirements of study patients.

Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation).

Time: From April to July 2020.

Description: Nutritional adaptation requirements (type of diet and need of nutritional supplementation).

Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation).

Time: From April to July 2020.

Description: Incidence of hospital readmissions: number of hospital readmissions/patient/6 months.

Measure: Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions).

Time: 6 months from inclusion.

Description: Prevalence: % of patients with hospital readmissions during the follow-up.

Measure: Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions).

Time: 6 months from inclusion.

Description: Incidence: number of visits to the emergency department/patient/6 months.

Measure: Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department).

Time: 6 months from inclusion.

Description: Prevalence: % of patients visiting the emergency department during the follow-up.

Measure: Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department).

Time: 6 months from inclusion.

Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).

Measure: Clinical complications at 6 months follow up from patient's medical history (respiratory complications).

Time: 6 months from inclusion.

Description: 6 months mortality.

Measure: Clinical complications at 6 months follow up from patient's medical history (mortality).

Time: 6 months from inclusion.


HPO Nodes


HP:0002015: Dysphagia
Genes 480
SMC1A SPG7 DKK1 FUS MYOT ATP7A PLA2G6 POLR3A IDH2 ALS2 ARHGAP29 PTS REPS1 ATP1A3 YARS2 TWNK RRM2B GBA CACNA1A SPART SCN4A CHRND GABRD SDHC SOD1 ADH1C PLAA LINGO1 SDHD PNKD SETBP1 KY MYH7 POLR3A SACS GLUD2 TBK1 GBA SLC6A9 TOP3A POLG FTL GRHL3 TRNK SLC19A3 BRAF MAP2K2 NEB GRHL2 MED17 NDUFA6 NECTIN1 SLC5A7 PRKCG ZFYVE26 C12ORF65 PIK3R5 MID1 SLC52A3 ACTA1 GDAP2 MAPT TK2 RYR1 VAMP1 RARS1 ATXN3 LRRK2 QDPR ND3 TBC1D23 DGUOK ACOX1 CACNA1G ATP6 SNCA ACTG2 ACTA1 GJB1 COL7A1 VPS35 LMX1B NDUFB8 C9ORF72 ADCY6 ATXN3 SNCA ACTA1 NEK1 HPRT1 POLG VAMP1 ERLIN2 ATXN3 CHMP2B CHRND TIMM8A NCAPG2 OPTN SLC25A22 REEP1 TK2 CACNA1G GIGYF2 UBQLN2 FARS2 POLG2 COQ4 SEMA3E NUP62 NEB GMPPA VPS13A TAF1 NF1 POLG SLC9A6 IRF6 HLA-DRB1 SLC25A4 ACTB CHRNE MFF ANKRD11 SYT14 SQSTM1 HOXB1 LAMB2 SLC52A2 SPECC1L TPM2 TRAPPC12 KLHL41 STXBP1 DLG1 CHCHD10 SPG21 ND1 ERLIN2 TGM6 FXN LMOD3 SDHB MAPT PIGA GBA2 GCH1 VARS1 KIAA0319L SPG21 CCR6 ND6 ASCC1 UBTF ND2 SLC5A7 PSAP CDH1 GBA ATXN8 LAMA2 ATXN2 CYP7B1 ASPA GBA POLR3A SLC52A2 SLC1A4 SPG7 NPC1 CTNS CARS2 RERE SNCA NDUFS2 TPM3 SQSTM1 TUBB4A COL7A1 PRPS1 PCNA PTS AGRN AR FTL CHRNA1 XRCC1 PRKRA ATXN1 SNAP25 KIT LMNB1 HGSNAT NONO UBTF SLC25A1 MECR CAV1 AFG3L2 MEGF10 ASAH1 REEP1 CCR6 TARDBP CCN2 NDUFS1 EBF3 CHRNE MSX1 KBTBD13 MAPT PANK2 HLA-DRB1 TRAPPC12 RAI1 EIF4G1 TRNV DDHD2 SLC18A3 KIT CLCN1 NOP56 PANK2 ATP13A2 KIT CHMP1A HTT PLXND1 NOTCH3 TUBB6 TANGO2 ATP7B SCN4A STUB1 COL7A1 CHAT CYP27A1 SETX NEFH TRNW PFN1 PRPH ALDH18A1 SDHC PRDM16 ATXN10 NGLY1 SNCAIP COLQ ATXN7 IRF2BPL COLQ ALS2 VAMP1 CNTNAP2 SKI MYOT NECTIN1 PSEN1 NDUFAF3 KCNAB2 TK2 CHAT CARMIL2 SYT14 POLG WFS1 ADD3 LMNB1 SCO2 IRF6 ND4 SETX COL7A1 TPM3 TWNK B4GALNT1 POLR3B FLAD1 MAPT LBR EPRS1 TAF1 PEX16 YY1 DNM1L FBXL4 RERE UBB SCN4A NEUROD2 MMP1 GNAO1 KLHL40 CHD7 RHBDF2 DAB1 SLC52A3 RRM2B CNTNAP1 KCNK9 SERPING1 EXOSC9 REV3L SURF1 MAPT SELENON TRIP4 C19ORF12 APP DGUOK ATP1A3 ATXN2 POLG QDPR CACNA1A PYROXD1 GFPT1 CAVIN1 PLA2G6 PDGFRA PRKRA DLX4 NRXN1 MYO9A MECP2 TP63 NDUFS3 MATR3 POLR3B GNS ACTA1 DYSF CHRNA1 AFG3L2 ATXN8 ARX KCNK9 MATR3 RLIM PANK2 TAF1 TUBB4A TPM2 CRYAB CAV1 NR4A2 ALS2 RNASEH1 GRM1 SCN3A ACTA1 SCN4A ATXN1 COQ2 MPZ ADNP NGLY1 DNAJC13 TTBK2 MYO9A TRNL1 RRM2B NDUFA9 NOP56 SON PRNP LIFR ATN1 POLG ALS2 TPM3 FBXO7 PLP1 NDUFAF2 NPC2 SDHB SPG7 LRP12 RNASEH1 FA2H PLEC ITGB4 IRX5 PIGN SDHA PUS3 TBK1 GEMIN4 MYORG COL7A1 MAPT ND5 MYPN SDHB DCTN1 SDHC DNAJB6 PLEC HLA-B MGME1 CDC73 MYMK GBA PLAA ATXN8OS IRF5 KLHL41 NUP62 STUB1 TYMP KMT2A OPA1 TP63 IKZF1 ATP1A3 KLHL7 ATXN7 GNAQ PUF60 DNAJB6 ATP6 NEB DMPK PABPN1 ATXN3 COL13A1 VAC14 NEB SIK1 GUCY1A1 SCARB2 MMP1 ECM1 FMR1 TANGO2 TIMM8A TBP FLCN SLC9A6 ATXN8OS KIF5A RRM2B ATXN8OS BMP4 FRG1 CDC73 IRF5 FERMT1 IDH1 ERLIN2 TPM3 KLHL41 KAT6B HPCA VAMP1 SLC52A3 PMP22 DDHD2 PDP1 VAPB MYH8 KCND3 SYT2 PANK2 ADAR SPG11 PDE8B GRIN2D MSX1 TBCD VCP SYNJ1 CHCHD10 CCN2 TBP KCNC3 KLHL40 MACF1 TARDBP
Protein Mutations 1
V158M
SNP 0